FY2028 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright lifted their FY2028 earnings per share estimates for Sangamo Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of $0.64 per share for the year, up from their prior estimate of $0.63. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.51) per share.

Several other brokerages have also weighed in on SGMO. StockNews.com upgraded shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Barclays raised their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday.

Sangamo Therapeutics Stock Down 4.7 %

Sangamo Therapeutics stock traded down $0.10 on Friday, hitting $2.05. The company's stock had a trading volume of 6,587,416 shares, compared to its average volume of 6,928,615. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The firm has a market cap of $427.67 million, a P/E ratio of -2.69 and a beta of 1.10. The company has a fifty day moving average price of $1.30 and a 200-day moving average price of $0.85.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. State Board of Administration of Florida Retirement System grew its holdings in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Sangamo Therapeutics during the 2nd quarter worth about $67,000. Meritage Portfolio Management grew its holdings in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 6,740 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Sangamo Therapeutics in the 2nd quarter valued at about $89,000. Finally, XTX Topco Ltd raised its stake in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 64,981 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.